Guardant Health, Inc.

NASDAQ:GH

Medical - Diagnostics & Research

Healthcare
$145.14 +2.07%

+$2.67 today

Market cap
$19.64B
Beta
1.62
P/E (TTM)
-39.9
EPS (TTM)
-$3.30
52W Low $40.35High $135.00

Volume 1.50M

Average 2.21M

GH Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Guardant Health, Inc.NASDAQ: GH

Gross Margin · Q3 FY2026 · quarter ended Sep 2026

Gross margin widens to 65.4%

Gross margin was 65.4% in Q3 FY2026, up 0.7 pp from a year earlier. On a trailing-twelve-month basis it was 65.2%, up 1.4 pp year over year. Over 3 fiscal years it narrowed by 0.8 pp.

Context

  • Gross margin widened in 2 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
65.4%+0.0 pp QoQ
Last fiscal yearDec 2025
64.5%+3.7 pp YoY
LTMSep 2026
65.2%+1.4 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+0.7 pp——
1 year+3.7 pp——
3 years-0.8 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
64.5%
Year-over-year change
+3.7pp

Gross Margin vs competitors

How GH compares with its peers on the latest reported figures

  • GH's LTM Sep 2026 gross margin of 65.2% is the 6th highest of the 10 companies compared; the peer median is 65.3%.
  • Its year-over-year change of +1.4 pp is the 5th highest of 10, against a peer median of -0.0 pp.
  • Over three fiscal years its change of -0.8 pp compares with a peer median of +2.7 pp.
GH Competitors Peer median
Gross Margin for GH and competitors
Company Period LTM level YoY 3-year change
BDSXBiodesix, Inc.LTM Mar 202682.1% +3.7 pp+18.1 pp
CSTLCastle Biosciences, Inc.LTM Mar 202677.1% -4.9 pp+2.7 pp
BLLNBillionToOne, Inc.LTM Jun 202671.3% +10.3 pp—
MYGNMyriad Genetics, Inc.LTM Mar 202670.0% -0.0 pp-0.3 pp
NTRANatera, Inc.LTM Jun 202665.3% +2.4 pp+20.5 pp
GHGuardant Health, Inc.LTM Sep 202665.2% +1.4 pp-0.8 pp
NEONeoGenomics, Inc.LTM Jun 202642.9% -1.0 pp+2.0 pp
FLGTFulgent Genetics, Inc.LTM Mar 202638.7% -0.1 pp-18.7 pp
PSNLPersonalis, Inc.LTM Mar 202613.7% -19.6 pp—
GRALGRAIL, Inc.LTM Jun 2026-10.8% +45.7 pp+167.1 pp
Peer median (excluding GH) 65.3%-0.0 pp+2.7 pp

Competitors are the stored peer set for GH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue373.65M449.54M563.95M739.02M982.02M
Cost of Revenue122.91M156.33M227.05M289.8M349.01M
Gross Profit250.74M293.21M336.9M449.22M633.01M
Gross Margin67.1%65.2%59.7%60.8%64.5%
Research & Development263.22M373.81M367.19M347.75M364.19M
Selling, General & Admin398.52M463.78M451.03M545.06M706.07M
Operating Expenses661.74M837.59M901.62M892.81M1.07B
Depreciation & Amortization22.27M35.96M42.88M42.39M39.74M
EBITDA(359.62M)(614.91M)(433.31M)(390.12M)(373.91M)
EBITDA Margin-96.2%-136.8%-76.8%-52.8%-38.1%
Operating Income(411M)(544.38M)(564.73M)(443.59M)(437.25M)
Operating Margin-110.0%-121.1%-100.1%-60.0%-44.5%
Interest Income3.93M6.07M35.37M53.69M34.1M
Interest Expense2.58M2.58M2.58M2.58M3.9M
Other Income / Expenses26.53M(109.07M)85.96M8.51M19.71M
Income Before Tax(384.47M)(653.45M)(478.76M)(435.09M)(417.54M)
Pre-Tax Margin-102.9%-145.4%-84.9%-58.9%-42.5%
Income Tax Expense300K1.14M685K1.28M(1.26M)
Net Income(405.67M)(654.59M)(479.45M)(436.37M)(416.28M)
Net Margin-108.6%-145.6%-85.0%-59.0%-42.4%
EPS (Basic)(4.00)(6.41)(4.28)(3.56)(3.32)
EPS (Diluted)(4.00)(6.41)(4.28)(3.56)(3.32)
Weighted Avg Shares101.31M102.18M111.99M122.75M125.37M
Weighted Avg Shares (Diluted)101.31M102.18M111.99M122.75M125.37M

Guardant Health, Inc.

NASDAQ:GH

Intrinsic Alpha fair value

Locked

Current Price

$145.14

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.